Company intelligence / Profile preview
Global Cancer Technology
- Ownership
- Private
- Development stage
- Preclinical
Overview
GCT’s lead program—a brain penetrating small molecule PI3K inhibitor—has shown preclinical efficacy in inducing growth arrest, increasing immune recognition, and sensitizing cancer cells to radiation. The company has completed preclinical trials with glioblastoma cultures and animal studies are ongoing. Plans are underway to initiate a Phase I clinical trial for glioblastoma by late 2024. Early preclinical results have also been reported for psoriasis.
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- Small molecule inhibitors (notably PI3K inhibitors)Nanoparticle-based drug delivery (scintillating nanoparticles)High Intensity Focused Ultrasound (HIFU)Boiling histotripsy
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Global Cancer Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Global Cancer Technology.